Ward-Based High-Flow Nasal Oxygen Therapy in Acute Respiratory Failure: A Retrospective Analysis of Long-Term Mortality
Respiration · 2025
DOI: 10.1159/000548033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Respiration, 2025. Verfasst von Christian Michael Horvath und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, …. Hauptthemen laut MEDLINE: Oxygen Inhalation Therapy, Respiratory Insufficiency, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
High-flow nasal oxygen therapy (HFNO) for acute respiratory failure (ARF) has been used in the intensive care units (ICUs), but more recently also on respiratory wards (RWs). Little data are available regarding in-hospital, short-term and long-term mortality in the latter setting.
Methods
We performed a retrospective analysis of patients ≥ 16 years old treated with HFNO on the RW between 01/2020 and 09/2022 with a follow-up until 09/2023. We grouped patients by main diagnosis and do-not-intubate (DNI) order. Cox proportional hazard models were used.
Results
We analyzed 145 HFNO patients (36% women, median age 70 years [quartile range {Q1–Q3} 62–79], BMI 25.8 [Q1-Q3: 22.6–28.5] kg/m2) with ARF mostly due to COVID-19 (n = 84, 57.9%), other pneumonia (n = 25, 17.2%), and mixed other diagnoses (n = 36, 25%). A total of 71 (48.9%) patients started HFNO on ICU and continued on the RW, treatment was tolerated in 94% of patients. In-hospital mortality was 24.8% (n = 35), of whom 33 patients had a DNI-order. The mortality rates after 30 days, 90 days, and 1 year were 30% (n = 44), 38% (n = 54), and 43% (n = 62). Long-term mortality did not differ between diagnostic groups (p > 0.05), a higher BMI was associated with lower mortality (hazard ratio [HR] 0.95 [95% CI 0.91–0.99]). A DNI-order and a palliative setting were associated with higher mortality (1 year: HR 3.03 [95% CI 1.15–7.69], p = 0.024 and HR 4.01 [2.21–7.26], p < 0.001).
Conclusion
In our cohort of patients with ARF treated with HFNO, the underlying diagnosis of ARF was not associated with an increased mortality risk. In DNI patients, RW HFNO allows for advanced care without burdening ICU resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, horvathchristianmichael@gmail.com.
- Department of Pulmonary Medicine, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Zitieren
APA
Horvath, C. M., Himmelrich, D. M., Guler, S. A., Günther, G., & Brill, A. K. (2025). Ward-Based High-Flow Nasal Oxygen Therapy in Acute Respiratory Failure: A Retrospective Analysis of Long-Term Mortality. Respiration. https://doi.org/10.1159/000548033
Vancouver
Horvath CM, Himmelrich DM, Guler SA, Günther G, Brill AK. Ward-Based High-Flow Nasal Oxygen Therapy in Acute Respiratory Failure: A Retrospective Analysis of Long-Term Mortality. Respiration. 2025. doi:10.1159/000548033
BibTeX
@article{Horvath2025,
author = {Horvath, Christian Michael and Himmelrich, Dominik Michael and Guler, Sabina A and Günther, Gunar and Brill, Anne-Kathrin},
title = {Ward-Based High-Flow Nasal Oxygen Therapy in Acute Respiratory Failure: A Retrospective Analysis of Long-Term Mortality},
journal = {Respiration},
year = {2025},
doi = {10.1159/000548033}
}
EUVIMED